Background: In cancer, tumor escape from the host immune system includes apoptosis of circulating CD3(+)CD8(+) effector T lymphocytes. Here, we compare sensitivity to apoptosis of virus- with tumor-specific circulating CD8(+) T cells in patients with head and neck cancer.

Methods: Wild-type p53 peptide-specific (p53(264-272) and p53(149-157)) and viral peptide-specific (EBV BMLF(259-267) and CMVpp65(495-503)) tetramers were used to measure the frequency of reactive T cells by flow cytometry. Annexin V (ANX) binding to circulating 7-amino-actinomycin D-negative but tetramer(+)CD8(+) T cells in PBMC obtained from 21 patients with head and neck cancer and 11 normal controls (NC) was evaluated.

Results: In patients with head and neck cancer, a higher percentage of tetramer(+)CD8(+) than tetramer(-)CD8(+) T cells bound ANX (p < .023-.005). Although most tumor-epitope(+)CD8(+) T cells bound ANX, lower percentages of virus-specific CD8(+) T cells were ANX(+) in the same patients.

Conclusions: Preferential demise of circulating tumor-specific CD8(+) T cells and their paucity in head and neck cancer contribute to tumor escape.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721365PMC
http://dx.doi.org/10.1002/hed.21031DOI Listing

Publication Analysis

Top Keywords

head neck
20
patients head
16
neck cancer
16
cd8+ cells
12
tumor escape
8
cells bound
8
bound anx
8
cells
7
head
5
neck
5

Similar Publications

Impact of Proposed Medicare Policy Changes for Botulinum Toxin Coverage on Hemifacial Spasm and Facial Dystonia.

Facial Plast Surg Aesthet Med

January 2025

Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head & Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is a primary liver malignancy characterized by high morbidity and mortality. Recently, ferroptosis has been recognized as an important factor in regulating cell growth in HCC. However, the role of ferroptosis-related genes in HCC remains unclear.

View Article and Find Full Text PDF

Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer.

Adv Sci (Weinh)

January 2025

Department of General Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine; National Experimental Teaching Center of Basic Medical Science, Department of Medical Genetics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, 211166, China.

Colorectal cancer (CRC) is highly resistant to ferroptosis, which hinders the application of anti-ferroptosis therapy. Through drug screening, it is found that histone deacetylase inhibitor (HDACi) significantly sensitized CRC to ferroptosis. The combination of HDACi and ferroptosis inducers synergically suppresses CRC growth both in vivo and in vitro.

View Article and Find Full Text PDF

Aim: Hearing loss is a public health issue; further studies are warranted to elucidate preventable factors. This study aimed to explore the associations of bilateral high-frequency hearing loss (HFHL) with examination data and lifestyle behaviors, using the Comprehensive Health Checkup System (Ningen Dock) data in Japan.

Methods: This cross-sectional study used Ningen Dock data obtained from the Seirei Health Care Division for 2020.

View Article and Find Full Text PDF

Introduction: A recent pan-cancer transcriptome analysis indicated differential activity of alternative promoters of genes TNS3 and LRRFIP1 in head and neck squamous cell carcinoma compared to non-cancerous tissue. The promoters upregulated in head and neck squamous cell carcinoma regulate expression of transcripts TNS3-203 and LRRFIP1-211.

Objective: Our aim was to investigate the biomarker potential of TNS3-203 and LRRFIP1-211 transcripts in oral cancer, the most common type of head and neck cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!